|Articles|September 1, 2001

Depression and Generalized Anxiety Disorder: Managed Care Considerations
Volume 7
Issue 11 Suppl

The Pharmacoeconomics of Venlafaxine in Depression

Author(s)Thomas J. Morrow, MD

Download PDF: The Pharmacoeconomics of Venlafaxine in Depression

Articles in this issue

almost 25 years ago

Article

Participating Faculty

almost 25 years ago

Article

Introduction

almost 25 years ago

Article

Current Perspectives on the Diagnosis and Treatment of Major Depressive Disorder

almost 25 years ago

Article

Recent Perspectives on the Diagnosis and Treatment of Generalized Anxiety Disorder

almost 25 years ago

Article

The Clinical, Psychosocial, and Pharmacoeconomic Ramifications of Remission

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Orthopedic surgeon holds bone x-ray | Image Credit: © tippapatt - stock.adobe.com

Musculoskeletal Quality Collaborative Improves Value-Based Health Care Delivery Across Hospital System

ByHannah I. Travers, MD,Mikhail Kuznetsov, MD,John Mazzocco, MD,Nicholas Pagani, MD,Tricia Ide, DNP, RN,Brian L. Hollenbeck, MD,Eric L. Smith, MD

June 3rd 2026

The Pharmacoeconomics of Venlafaxine in Depression

Articles in this issue

Related Content

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Musculoskeletal Quality Collaborative Improves Value-Based Health Care Delivery Across Hospital System

Trending on AJMC

Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata

Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story

First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA

Endometriosis Reduces Ovarian Reserve via Inflammation and Surgery

From EASL 2026: What Hepatology Still Needs to Solve